Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder.

Butters MA, Bhalla RK, Andreescu C, Wetherell JL, Mantella R, Begley AE, Lenze EJ.

Br J Psychiatry. 2011 Sep;199(3):211-8. doi: 10.1192/bjp.bp.110.090217. Epub 2011 Jul 4.

2.

Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.

Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, Costantino M, Snyder S, Shi P, Spitznagel E, Andreescu C, Butters MA, Reynolds CF 3rd.

JAMA. 2009 Jan 21;301(3):295-303. doi: 10.1001/jama.2008.977.

3.

Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder.

Rosnick CB, Rawson KS, Butters MA, Lenze EJ.

Aging Ment Health. 2013;17(4):432-40. doi: 10.1080/13607863.2012.761673. Epub 2013 Jan 22.

4.

Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment.

Blank S, Lenze EJ, Mulsant BH, Dew MA, Karp JF, Shear MK, Houck PR, Miller MD, Pollock BG, Tracey B, Reynolds CF.

J Clin Psychiatry. 2006 Mar;67(3):468-72.

PMID:
16649835
5.

Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy.

Tempesta D, Mazza M, Serroni N, Moschetta FS, Di Giannantonio M, Ferrara M, De Berardis D.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:236-41. doi: 10.1016/j.pnpbp.2013.06.006. Epub 2013 Jun 21.

PMID:
23796524
6.

Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.

Lenze EJ, Dixon D, Mantella RC, Dore PM, Andreescu C, Reynolds CF 3rd, Newcomer JW, Butters MA.

Int J Geriatr Psychiatry. 2012 May;27(5):454-62. doi: 10.1002/gps.2732. Epub 2011 Jun 17.

7.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
8.

Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.

Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R.

Arch Gen Psychiatry. 2008 May;65(5):551-62. doi: 10.1001/archpsyc.65.5.551.

PMID:
18458207
9.

Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes.

Stein DJ, Andersen HF, Goodman WK.

Ann Clin Psychiatry. 2005 Apr-Jun;17(2):71-5.

PMID:
16075659
10.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Davidson JR, Bose A, Korotzer A, Zheng H.

Depress Anxiety. 2004;19(4):234-40.

PMID:
15274172
11.

Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.

Davidson JR, Bose A, Wang Q.

J Clin Psychiatry. 2005 Nov;66(11):1441-6.

PMID:
16420082
12.

Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial.

Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF 3rd.

Am J Psychiatry. 2005 Jan;162(1):146-50.

PMID:
15625213
13.

Escitalopram and enhancement of cognitive recovery following stroke.

Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG.

Arch Gen Psychiatry. 2010 Feb;67(2):187-96. doi: 10.1001/archgenpsychiatry.2009.185.

14.

Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.

Allgulander C, Jørgensen T, Wade A, François C, Despiegel N, Auquier P, Toumi M.

Curr Med Res Opin. 2007 Oct;23(10):2543-9.

PMID:
17825130
15.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817
16.

Escitalopram for persistent symptoms of generalized anxiety disorder after CBT: a pilot study.

Schneier FR, Belzer KD, Kishon R, Amsel L, Simpson HB.

J Nerv Ment Dis. 2010 Jun;198(6):458-61. doi: 10.1097/NMD.0b013e3181da4d77.

PMID:
20531128
17.

Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.

Rocca P, Calvarese P, Faggiano F, Marchiaro L, Mathis F, Rivoira E, Taricco B, Bogetto F.

J Clin Psychiatry. 2005 Mar;66(3):360-9.

PMID:
15766303
18.

Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.

Lenze EJ, Mantella RC, Shi P, Goate AM, Nowotny P, Butters MA, Andreescu C, Thompson PA, Rollman BL.

Am J Geriatr Psychiatry. 2011 May;19(5):482-90. doi: 10.1097/JGP.0b013e3181ec806c.

19.

Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.

Rosnick CB, Wetherell JL, White KS, Andreescu C, Dixon D, Lenze EJ.

J Consult Clin Psychol. 2016 Apr;84(4):345-52. doi: 10.1037/a0040113. Epub 2016 Feb 15.

20.

Mood and neuropsychological changes in women with midlife depression treated with escitalopram.

Wroolie TE, Williams KE, Keller J, Zappert LN, Shelton SD, Kenna HA, Reynolds MF, Rasgon NL.

J Clin Psychopharmacol. 2006 Aug;26(4):361-6.

PMID:
16855452

Supplemental Content

Support Center